SPCG-4随机试验:根治性前列腺切除术与观察等待的结局时间依赖性
SPCG-4试验将695例早期前列腺癌患者随机分配至根治性前列腺切除术(RP)或观察等待(WW),随访显示前列腺癌死亡率在RP组从5年2.9%升至30年25.9%,WW组从4.6%升至42.9%,绝对风险降低从1.7%增至17.0%,需治疗人数从58降至6。
要点
- RP组30年前列腺癌累积死亡率为25.9%,WW组为42.9%。
- 绝对风险降低从5年1.7%增至30年17.0%,NNT从58降至6。
- 随访10-15年时WW组合并症高于RP组。
核心结论
- 早期前列腺癌治疗选择具有终身后果,结局高度依赖随访时间。
研究设计与样本
- SPCG-4随机试验,1989-1999年纳入695例早期前列腺癌患者,随机分为RP组或WW组,在意向治疗人群中进行分析。
主要发现
- RP组前列腺癌累积死亡率从5年2.9%升至30年25.9%,WW组从4.6%升至42.9%。
- 绝对风险降低从1.7%增至17.0%,需治疗人数从58降至6。
- 随访10-15年时WW组合并症高于RP组。
- 以随机化后存活满20年为条件时,RP组获得生命年增益。
临床怎么用
- 临床决策时应考虑RP与WW的获益随时间变化,长期随访显示RP降低前列腺癌死亡风险且绝对获益随时间增大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We synthesized life-long trends for outcome measures following radical prostatectomy or watchful waiting in the SPCG-4 trial, which randomized 695 patients with early prostate cancer to radical prostatectomy (RP) or watchful waiting (WW) from 1989 to 1999. We estimated trends in the relative risk of prostate cancer death, absolute risk reduction (ARR), number needed to treat (NNT), life-years gained, and changes in comorbidity following RP versus WW in the intention-to-treat population. During follow-up after randomization, cumulative prostate cancer mortality increased from 2.9% at 5 yr to 25.9% at 30 yr in the RP arm, and from 4.6% at 5 yr to 42.9% at 30 yr in the WW arm, with a corresponding increase in ARR from 1.7% to 17.0%. NNT to avert one prostate cancer death decreased from 58 to 6. Life-years were gained when follow-up was conditioned on being alive up to 20 yr after randomization. At 10-15 yr of follow-up, the WW arm had higher comorbidity than the RP arm. Treatment choices for early prostate cancer have lifelong consequences. Trial outcomes in a disease with long natural history are highly time-dependent.
引用
- Holmberg L, Garmo H, Andersson SO, et al. Time Dependence of Outcomes in the SPCG-4 Randomized Trial Comparing Radical Prostatectomy and Watchful Waiting in Early Prostate Cancer. Eur Urol. 2025. PMID: 40744802. doi:10.1016/j.eururo.2025.07.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。